Silo Pharma Inc

This management proposal requests shareholder approval to amend the Articles of Incorporation to increase authorized common shares from 6,666,667 to 250,000,000. Management frames the amendment as necessary to provide the company with capital-raising and strategic flexibility, including the ability to issue equity in connection with financings, acquisitions, strategic partnerships, and equity incentive plans, and explicitly cites potential acquisitions of IVF clinics as an objective to reach cash-flow breakeven. The Board argues that having additional authorized shares avoids the delay and expense of calling a special shareholder vote each time new shares are needed. The filing acknowledges dilution risks: additional authorized shares could reduce existing shareholders’ percentage ownership, depress earnings per share, and negatively affect the market price if substantial sales occur or are perceived as likely. The Board disclaims any present plans to issue shares immediately but reserves the ability, under Board discretion, to file the amendment if approved and also reserves the right not to proceed even after approval if it deems it not in shareholders’ best interests. The vote required is a majority of votes cast (excluding abstentions), and the Board unanimously recommends a vote FOR the proposal. From a governance perspective, the amendment increases the Board’s toolbox but shifts dilution control to management and the Board; shareholders should weigh the operational need for flexibility against the potential for dilution and the absence of preemptive rights. Given the company’s limited outstanding float (1,128,610 shares outstanding as of the record date) and active use of equity historically for financing and compensation, approval materially expands the shares the company could issue and therefore has tangible capital-raising consequences for investors.

This management proposal seeks shareholder authorization to allow the Board to adjourn the Annual Meeting — either to solicit additional proxies if there are insufficient votes to approve one or more proposals, or for any other reason the Board deems appropriate. In practice, the adjournment power is a routine procedural mechanism that lets the company reconvene the meeting at a later date without re-setting the record date (so long as the adjournment is under thirty days), enabling additional solicitation to obtain approval thresholds for non-routine items. The Board notes that if certain proposals have sufficient votes, those may be voted on and then the meeting adjourned as to remaining items; alternatively the Board may choose to put only the adjournment proposal to a vote. Shareholders retain the right to revoke proxies prior to the adjourned meeting, and only those entitled to vote at the original meeting may vote at the adjourned meeting unless a new record date is set. The Board recommends a vote FOR the proposal to preserve operational flexibility and reduce the risk that key proposals fail solely due to insufficient turnout or broker non-votes. While common and generally uncontroversial, the adjournment authority can be used strategically to extend solicitation and influence outcomes — shareholders should understand it is a tool for managing vote timing rather than a substantive governance change. The proposal requires a majority of votes cast (excluding abstentions) for approval. Given the company's small float and the board and insiders’ potential interest in certain compensatory matters, the adjournment authorization increases the Board’s ability to secure required approvals but does not itself alter economic rights of shareholders.